Cargando…
Antinociceptive and antitumor activity of novel synthetic mononuclear Ruthenium (II) compounds
BACKGROUND: From the thousands of years, metal compounds have been used in medicine for treatment of various diseases including various types of cancers. Ruthenium was seen as a promising metal due to its similar kinetics to platinum and its lower toxicity. Therefore, we aimed to evaluate the newer...
Autores principales: | Sunder A, Shyam, Dhulipala, Satyavati, Thota, Sreekanth, Yerra, Rajeshwar, Balzarini, Jan, De Clercq, Erik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732902/ https://www.ncbi.nlm.nih.gov/pubmed/23930118 |
Ejemplares similares
-
p-Cymene Complexes of Ruthenium(II) as Antitumor Agents
por: Pujante-Galián, María Angeles, et al.
Publicado: (2020) -
Synthesis of thiocarbohydrazide and carbohydrazide derivatives as possible biologically active agents
por: Gangarapu, Kiran, et al.
Publicado: (2013) -
Mononuclear ruthenium polypyridine complexes that catalyze water oxidation
por: Tong, Lianpeng, et al.
Publicado: (2016) -
New Heteroleptic Ruthenium(II) Complexes with Sulfamethoxypyridazine and Diimines as Potential Antitumor Agents
por: de Melo, Ariane C.C., et al.
Publicado: (2019) -
Ruthenium polypyridyl complexes and their modes of interaction with DNA: Is there a correlation between these interactions and the antitumor activity of the compounds?
por: Corral, Eva, et al.
Publicado: (2008)